Invesaro

Stocks Comparison

Myriad Genetics vs Alpha Teknova: revenue, profit, margins and growth compared

Myriad Genetics brought in $824.5M of revenue in fiscal 2025, Alpha Teknova $40.5M in fiscal 2025. Revenue changed by -1.6% at Myriad Genetics and +7.4% at Alpha Teknova on the year before, so Alpha Teknova grew faster. Myriad Genetics kept -44.4% of its revenue as net profit, Alpha Teknova -42.6%.

Side by side, latest fiscal year

MYGNTKNO
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$824.5M$40.5M
Revenue growth-1.6%+7.4%
Net income-$365.9M-$17.3M
Net margin-44.4%-42.6%
Free cash flown/a-$9.8M
Free cash flow marginn/a-24.2%
Earnings per share (diluted)-$3.95-$0.32
Cash$149.6M$5.9M
Debt$119.9M$13.1M
Price to earningsn/an/a
Market value$398.9M$500.9M
Dividend yieldn/an/a
Rank by revenue in sector#159 of 523 · Health care#376 of 523 · Health care

Over the years

Revenue
MYGN FY2019: $851.1MMYGN FY2020: $638.6MMYGN FY2020: $557.1MMYGN FY2021: $690.6MMYGN FY2022: $678.4MMYGN FY2023: $753.2MMYGN FY2024: $837.6MMYGN FY2025: $824.5MTKNO FY2021: $31.3MTKNO FY2021: $36.9MTKNO FY2022: $41.4MTKNO FY2023: $36.7MTKNO FY2024: $37.7MTKNO FY2025: $40.5MFY19FY20FY21FY22FY23FY24FY25
MYGN $824.5MTKNO $40.5M
Net income
MYGN FY2019: $4.6MMYGN FY2020: -$199.5MMYGN FY2020: -$223.6MMYGN FY2021: -$27.2MMYGN FY2022: -$112MMYGN FY2023: -$263.3MMYGN FY2024: -$127.3MMYGN FY2025: -$365.9MTKNO FY2021: $3.6MTKNO FY2021: -$9.8MTKNO FY2022: -$47.5MTKNO FY2023: -$36.8MTKNO FY2024: -$26.7MTKNO FY2025: -$17.3MFY19FY20FY21FY22FY23FY24FY25
MYGN -$365.9MTKNO -$17.3M
Net margin
MYGN FY2019: 0.5%MYGN FY2020: -31.2%MYGN FY2020: -40.1%MYGN FY2021: -3.9%MYGN FY2022: -16.5%MYGN FY2023: -35.0%MYGN FY2024: -15.2%MYGN FY2025: -44.4%TKNO FY2021: 11.4%TKNO FY2021: -26.6%TKNO FY2022: -114.6%TKNO FY2023: -100.3%TKNO FY2024: -70.9%TKNO FY2025: -42.6%FY19FY20FY21FY22FY23FY24FY25
MYGN -44.4%TKNO -42.6%
Revenue growth
MYGN FY2020: -25.0%MYGN FY2020: -12.8%MYGN FY2021: +24.0%MYGN FY2022: -1.8%MYGN FY2023: +11.0%MYGN FY2024: +11.2%MYGN FY2025: -1.6%TKNO FY2021: +17.9%TKNO FY2022: +12.3%TKNO FY2023: -11.4%TKNO FY2024: +2.9%TKNO FY2025: +7.4%FY20FY21FY22FY23FY24FY25
MYGN -1.6%TKNO +7.4%
Free cash flow
MYGN FY2019: $75.1MMYGN FY2020: $50.5MMYGN FY2021: $600KMYGN FY2022: -$151.6MTKNO FY2021: -$3MTKNO FY2021: -$28.9MTKNO FY2022: -$55.5MTKNO FY2023: -$26.7MTKNO FY2024: -$13.5MTKNO FY2025: -$9.8MFY19FY20FY21FY22FY23FY24FY25
MYGN -$151.6MTKNO -$9.8M

Fiscal years as each company reports them; the two may end in different months.

Questions about Myriad Genetics and Alpha Teknova

Which is bigger by revenue, Myriad Genetics or Alpha Teknova?

Myriad Genetics is bigger by revenue: $824.5M in fiscal 2025, against $40.5M for Alpha Teknova in fiscal 2025.

Which keeps more of its revenue as profit, Myriad Genetics or Alpha Teknova?

Myriad Genetics had a net margin of -44.4% in fiscal 2025; Alpha Teknova had -42.6% in fiscal 2025.

Which grew revenue faster, Myriad Genetics or Alpha Teknova?

In their latest fiscal years revenue changed by -1.6% at Myriad Genetics and +7.4% at Alpha Teknova.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies